Eli Lilly Shines as Branded Pharma Q1 Earnings Mixed; Zoetis Plunges 30%

Branded pharmaceutical companies posted mixed first-quarter results, with Eli Lilly (NYSE:LLY) surging past estimates and Zoetis (NYSE:ZTS) sliding sharply. The 11 stocks tracked by this report collectively beat revenue forecasts by 0.7% on average. Eli Lilly reported revenue of $19.8 billion, up 55.5% year-over-year and 13.7% above consensus, lifting its stock 29.8% since the announcement. Conversely, Zoetis missed revenue and earnings estimates, triggering a 30% stock decline. Bristol-Myers Squibb (NYSE:BMY) beat revenue expectations by 7.4% with $11.49 billion but issued full-year EPS guidance slightly below analysts’ projections, leaving the stock flat. Pfizer (NYSE:PFE) similarly exceeded revenue forecasts but lowered its annual profit outlook; shares were unchanged. Collegium Pharmaceutical (NASDAQ:COLL) topped revenue estimates but gave weaker full-year guidance, sending the stock down 8%.